These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 17046544

  • 1. Postprandial thrombin activatable fibrinolysis inhibitor and markers of endothelial dysfunction in type 2 diabetic patients.
    Rigla M, Wägner AM, Borrell M, Mateo J, Foncuberta J, de Leiva A, Ordóñez-Llanos J, Pérez A.
    Metabolism; 2006 Nov; 55(11):1437-42. PubMed ID: 17046544
    [Abstract] [Full Text] [Related]

  • 2. The role of dietary cholesterol in the regulation of postprandial apolipoprotein B48 levels in diabetes.
    Taggart C, Gibney J, Owens D, Collins P, Johnson A, Tomkin GH.
    Diabet Med; 1997 Dec; 14(12):1051-8. PubMed ID: 9455933
    [Abstract] [Full Text] [Related]

  • 3. Insulin resistance is independently associated with postprandial alterations of triglyceride-rich lipoproteins in type 2 diabetes mellitus.
    Annuzzi G, De Natale C, Iovine C, Patti L, Di Marino L, Coppola S, Del Prato S, Riccardi G, Rivellese AA.
    Arterioscler Thromb Vasc Biol; 2004 Dec; 24(12):2397-402. PubMed ID: 15458975
    [Abstract] [Full Text] [Related]

  • 4. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
    Kitagawa N, Yano Y, Gabazza EC, Bruno NE, Araki R, Matsumoto K, Katsuki A, Hori Y, Nakatani K, Taguchi O, Sumida Y, Suzuki K, Adachi Y.
    Diabetes Res Clin Pract; 2006 Aug; 73(2):150-7. PubMed ID: 16458385
    [Abstract] [Full Text] [Related]

  • 5. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
    Yener S, Comlekci A, Akinci B, Demir T, Yuksel F, Ozcan MA, Bayraktar F, Yesil S.
    Med Princ Pract; 2009 Aug; 18(4):266-71. PubMed ID: 19494532
    [Abstract] [Full Text] [Related]

  • 6. Postprandial apolipoprotein B48-and B100-containing lipoproteins in type 2 diabetes: do statins have a specific effect on triglyceride metabolism?
    Battula SB, Fitzsimons O, Moreno S, Owens D, Collins P, Johnson A, Tomkin GH.
    Metabolism; 2000 Aug; 49(8):1049-54. PubMed ID: 10954025
    [Abstract] [Full Text] [Related]

  • 7. Hepatic fat content is a determinant of postprandial triglyceride levels in type 2 diabetes mellitus patients with normal fasting triglyceride.
    Nimitphong H, Phongkitkarun S, Rattarasarn C, Kongsooksai A, Chanprasertyothin S, Bunnag PA, Puavilai G.
    Metabolism; 2008 May; 57(5):644-9. PubMed ID: 18442627
    [Abstract] [Full Text] [Related]

  • 8. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N, Guldiken S, Demir M, Tugrul A.
    Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
    [Abstract] [Full Text] [Related]

  • 9. The effect of short-term glycemic regulation with gliclazide and metformin on postprandial lipemia.
    Emral R, Köseoğlulari O, Tonyukuk V, Uysal AR, Kamel N, Corapçioğlu D.
    Exp Clin Endocrinol Diabetes; 2005 Feb; 113(2):80-4. PubMed ID: 15772898
    [Abstract] [Full Text] [Related]

  • 10. Normalisation of tissue factor pathway inhibitor activity after glycaemic control optimisation in type 1 diabetic patients.
    Rigla M, Mateo J, Fontcuberta J, Souto JC, de Leiva A, Pérez A.
    Thromb Haemost; 2000 Aug; 84(2):223-7. PubMed ID: 10959693
    [Abstract] [Full Text] [Related]

  • 11. Impact of simvastatin on hemostatic and fibrinolytic regulators in Type 2 diabetes mellitus.
    Ludwig S, Dharmalingam S, Erickson-Nesmith S, Ren S, Zhu F, Ma GM, Zhao R, Fenton JW, Ofosu FA, Velthuis HT, van Mierlo G, Shen GX.
    Diabetes Res Clin Pract; 2005 Nov; 70(2):110-8. PubMed ID: 16188573
    [Abstract] [Full Text] [Related]

  • 12. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
    Ceriello A, Del Prato S, Bue-Valleskey J, Beattie S, Gates J, de la Peña A, Malone J.
    J Diabetes Complications; 2007 Nov; 21(1):20-7. PubMed ID: 17189870
    [Abstract] [Full Text] [Related]

  • 13. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
    Chudý P, Kotuličová D, Staško J, Kubisz P.
    Blood Coagul Fibrinolysis; 2011 Sep; 22(6):493-8. PubMed ID: 21519232
    [Abstract] [Full Text] [Related]

  • 14. Real-time assessment of postprandial fat storage in liver and skeletal muscle in health and type 2 diabetes.
    Ravikumar B, Carey PE, Snaar JE, Deelchand DK, Cook DB, Neely RD, English PT, Firbank MJ, Morris PG, Taylor R.
    Am J Physiol Endocrinol Metab; 2005 Apr; 288(4):E789-97. PubMed ID: 15572652
    [Abstract] [Full Text] [Related]

  • 15. Postprandial lipid abnormalities in type 2 diabetes mellitus.
    Madhu SV, Mittal V, Ram BK, Srivastava DK.
    J Assoc Physicians India; 2005 Dec; 53():1043-6. PubMed ID: 16572960
    [Abstract] [Full Text] [Related]

  • 16. Physical training decreases plasma thrombomodulin in type I and type II diabetic patients.
    Rigla M, Fontcuberta J, Mateo J, Caixàs A, Pou JM, de Leiva A, Pérez A.
    Diabetologia; 2001 Jun; 44(6):693-9. PubMed ID: 11440361
    [Abstract] [Full Text] [Related]

  • 17. Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy.
    Małyszko J, Małyszko JS, Hryszko T, Myśliwiec M.
    Thromb Haemost; 2004 Mar; 91(3):480-6. PubMed ID: 14983223
    [Abstract] [Full Text] [Related]

  • 18. The effects of hyperglycaemia on thrombin-activatable fibrinolysis inhibitor.
    Verkleij CJ, Nieuwdorp M, Gerdes VE, Mörgelin M, Meijers JC, Marx PF.
    Thromb Haemost; 2009 Sep; 102(3):460-8. PubMed ID: 19718465
    [Abstract] [Full Text] [Related]

  • 19. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome.
    Oral B, Mermi B, Dilek M, Alanoğlu G, Sütçü R.
    Gynecol Endocrinol; 2009 Feb; 25(2):110-6. PubMed ID: 19253106
    [Abstract] [Full Text] [Related]

  • 20. Postprandial chylomicrons and adipose tissue lipoprotein lipase are altered in type 2 diabetes independently of obesity and whole-body insulin resistance.
    Annuzzi G, Giacco R, Patti L, Di Marino L, De Natale C, Costabile G, Marra M, Santangelo C, Masella R, Rivellese AA.
    Nutr Metab Cardiovasc Dis; 2008 Oct; 18(8):531-8. PubMed ID: 18321693
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.